Friday 6 November 2026 Export MDT’s income statement to Excel — free account

Medtronic PLC

Medtronic PLC’s revenue for fiscal 2026 (year ended April 2026) was $36.4 billion, up 8.43% from fiscal 2025.

Revenue: +13.7%
EPS: +42.0%
Free cash flow: +120.9%
Total debt: −1.59%

Quarter to July 2026, against a year earlier

102.26 2.58 −2.46%

Follow MDT

Alert me

Market cap: $134.1B
P/E: 25.6×
Fwd P/E: 20.8×
Dividend yield: 2.74%
F-score: 7/9
Altman Z: 2.73
Beneish M: −2.58
Dividend safety: 61/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Medtronic PLC (MDT) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2026: revenue by segment, and margins
Cardiovascular	13,976	38.43%
Neuroscience	10,287	28.29%
Medical Surgical	8,815	24.24%
Diabetes	3,112	8.56%
Other operating segment, misc	135	0.37%
Gross margin		65.02%
Operating margin		17.78%
Pre-tax margin		16.87%

Revenue by segment $m

Line	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013
Other operating segment, misc	135 0.37%	137 0.41%	221 0.68%	495 1.59%	727 2.29%	—	—	—	—	—	—	—	—	—
Also reported: a second breakdown of the same revenue
Cardiovascular	13,976 38.43%	12,481 37.22%	11,831 36.56%	11,522 36.90%	11,368 35.88%	10,772 35.77%	10,468 36.21%	11,505 37.65%	11,354 37.91%	10,498 35.33%	10,196 35.36%	9,361 46.20%	8,847 52.03%	8,695 52.41%
Neuroscience	10,287 28.29%	9,846 29.36%	9,406 29.06%	8,959 28.69%	8,784 27.72%	8,195 27.21%	7,725 26.72%	8,183 26.78%	7,743 25.85%	7,366 24.79%	7,210 25.01%	6,751 33.32%	6,501 38.23%	6,369 38.39%
Medical Surgical	8,815 24.24%	8,407 25.07%	8,417 26.01%	7,989 25.58%	8,469 26.73%	8,737 29.01%	8,352 28.89%	8,478 27.74%	8,716 29.10%	9,919 33.39%	9,563 33.17%	2,387 11.78%	0 0.00%	0 0.00%
Diabetes	3,112 8.56%	2,755 8.21%	2,488 7.69%	2,262 7.24%	2,338 7.38%	2,413 8.01%	2,368 8.19%	2,391 7.82%	2,140 7.14%	1,927 6.49%	1,864 6.46%	1,762 8.70%	1,657 9.74%	1,526 9.20%
Other Segment	—	—	—	495 1.59%	—	—	—	—	—	—	—	—	—	—
Other Operating Segments, Including Diabetes	3,247	2,892	2,710	—	—	—	—	—	—	—	—	—	—	—
Reportable segment net sales	33,079	30,734	29,654	—	30,959	—	—	—	—	—	—	—	—	—
Revenue	36,364	33,537	32,364	31,227	31,686	30,117	28,913	30,557	29,953	29,710	28,833	20,261	17,005	16,590

Operating income by segment $m, and margin

	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013
Cardiovascular	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Neuroscience	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Medical Surgical	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Diabetes	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Other Segment	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Other operating segment, misc	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Corporate and other	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Operating income	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

Revenue by region $m

Line	FY2026	FY2025	FY2024	FY2023	FY2016	FY2013
Rest of world	18,118 49.82%	16,250 48.45%	15,689 48.48%	14,756 47.25%	12,332 42.77%	—
UNITED STATES	18,103 49.78%	17,171 51.20%	16,562 51.17%	16,373 52.43%	16,422 56.96%	—
Ireland	143 0.39%	116 0.35%	113 0.35%	98 0.31%	79 0.27%	—
Americas	—	—	—	—	—	9,761 58.84%
Emea	—	—	—	—	—	4,225 25.47%
Asia Pacific	—	—	—	—	—	1,886 11.37%
China	—	—	—	—	—	718 4.33%
International	18,261	16,365	15,802	14,854	—	—
Total other countries, excluding Ireland	36,221	33,421	32,251	31,129	28,754	—
Revenue	36,364	33,537	32,364	31,227	28,833	16,590

Operating figures as reported in each quarter’s results release or filing

Figure	Quarter	Latest	A year before	Change
Remaining performance obligations	Q1 FY2027	$400.0M	$400.0M	0.00%

	Q1 FY2027	Q4 FY2026	Q3 FY2026	Q2 FY2026	Q1 FY2026	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025	Q4 FY2024	Q3 FY2024	Q2 FY2024	Q1 FY2024	Q4 FY2023	Q3 FY2023	Q2 FY2023	Q1 FY2023	Q4 FY2022	Q3 FY2022	Q2 FY2022	Q1 FY2022	Q4 FY2021	Q3 FY2021	Q2 FY2021	Q1 FY2021	Q4 FY2020	Q3 FY2020	Q2 FY2020	Q1 FY2020	Q4 FY2019	Q3 FY2019	Q2 FY2019	Q1 FY2019
Remaining performance obligations	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.